Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6430-6440

  Guéry, Leslie ^a   Dubrot, Juan ^a   Lippens, Carla ^a   Brighouse, Dale ^a   Malinge, Pauline ^b   Irla, Magali ^a,c   Pot, Caroline ^a,d   Reith, Walter ^a   Waldburger, Jean Marc ^a   Hugues, Stéphanie ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NOVIMMUNE SA   (Switzerland)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CYTIDYLYL-3'-5'-GUANOSINE; DINUCLEOSIDE PHOSPHATE; HLA ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOPATHOLOGY; LEUKOCYTE MIGRATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN DEPLETION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR IMMUNITY; TUMOR REGRESSION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; DENDRITIC CELLS; DINUCLEOSIDE PHOSPHATES; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TH17 CELLS;

EID: 84918502868     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1149     Document Type: Article

References (56)

1. Colonna M, Trinchieri G, Liu YJ Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219-26.
2. Villadangos JA, Young L. Antigen-presentation properties of plasma-cytoid dendritic cells. Immunity 2008; 29:352-61.
3. Isaksson M, Ardesjo B, Ronnblom L., Kampe O, Lassmann H, Eloranta M.L., et al. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. Eur J Immunol 2009; 39:2925-35.
4. Loschko J, Schlitzer A, Dudziak D., Drexler I, Sandholzer N, Bourquin C., et al. Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. J Immunol 2011; 186:6718-25.
5. de Heer H.J., Hammad H, Soullie T., Hijdra D, Vos N, Willart M.A., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200: 89-98.
6. Hadeiba H, Sato T, Habtezion A., Oderup C, Pan J, Butcher EC CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 2008; 9: 1253-60.
7. Ochando JC, Homma C, Yang Y., Hidalgo A, Garin A, Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7:652-62.
8. Loschko J, Heink S, Hackl D., Dudziak D, Reindl W, Korn T., et al. Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity. J Immunol 2011; 187:6346-56.
9. Irla M, Kupfer N, Suter T., Lissilaa R, Benkhoucha M, Skupsky J., et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J Exp Med 2010; 207:1891-905.
10. Sisirak V, Faget J, Gobert M., Goutagny N, Vey N, Treilleux I., et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-97.
11. Sharma MD, Baban B, Chandler P., Hou DY, Singh N, Yagita H, et al Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 2007; 117:2570-82.
12. Faget J, Bendriss-Vermare N, Gobert M., Durand I, Olive D, Biota C., et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72: 6130-41.
13. Conrad C, Gregorio J, Wang Y.H., Ito T., Meller S, Hanabuchi S, et al Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012; 72:5240-9.
14. Tel J, Aarntzen EH, Baba T, Schreibelt G., Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75.
15. Tel J, Sittig SP, Blom R.A., Cruz LJ, Schreibelt G, Figdor CG, et al Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol 2013; 191:5005-12.
16. Le Mercier I., Poujol D, Sanlaville A., Sisirak V, Gobert M, Durand I., et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; 73:4629-40.
17. Liu X, Zhan Z, Li D., Xu L, Ma F, Zhang P., et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011; 12:416-24.
18. Kontgen F, Suss G, Stewart C., Steinmetz M, Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 1993; 5:957-64.
19. LeibundGut-Landmann S., Waldburger JM, Reise Sousa C, Acha-Orbea H, Reith W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat Immunol 2004; 5:899-908.
20. Hogquist KA, Jameson SC, Heath W.R., Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27.
21. Barnden MJ, Allison J, Heath W.R., Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76:34-40.
22. Kitamura T, Takaku F, Miyajima A. IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1. Int Immunol 1991; 3:571-7.
23. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005; 5:793-806.
24. Waldburger JM, Suter T, Fontana A., Acha-Orbea H, Reith W. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med 2001; 194: 393-406.
25. Kadowaki N, Antonenko S, Liu YJ Distinct CpG DNA and poly-inosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166: 2291-5.
26. Muranski P, Boni A, Antony P.A., Cassard L., Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-73.
27. Ramakrishnan R, Assudani D, Nagaraj S., Hunter T, Cho HI, Antonia S, et al Chemotherapy enhances tumor cell susceptibility to CTL-medi-ated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-24.
28. Hariharan K, Braslawsky G, Black A., Raychaudhuri S, Hanna N. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 1995; 55:3486-9.
29. Boissonnas A, Fetler L, Zeelenberg I.S., Hugues S., Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007; 204:345-56.
30. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48.
31. Gilliet M, Cao W, Liu YJ Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606.
32. Wang BX, Rahbar R, Fish EN Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 2011; 31: 545-52.
33. Demoulin S, Herfs M, Delvenne P., Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolero-genic cells: insight into the molecular mechanisms. J Leukoc Biol 2013; 93:343-52.
34. Diamond MS, Kinder M, Matsushita H., Mashayekhi M, Dunn GP, Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989-2003.
35. Fuertes MB, Kacha AK, Kline J, Woo S.R., Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208: 2005-16.
36. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla J.P., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74.
37. Labidi-Galy S.I., Sisirak V, Meeus P., Gobert M, Treilleux I, Bajard A., et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423-34.
38. Liu C, Lou Y, Lizee G., Qin H, Liu S, Rabinovich B., et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118: 1165-75.
39. Young LJ, Wilson NS, Schnorrer P, Proietto A., ten Broeke T, Matsuki Y, et al Differential MHC class II synthesis and ubiqui-tination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 2008; 9: 1244-52.
40. O'Keeffe M., Grumont RJ, Hochrein H, Fuchsberger M., Gugasyan R, Vremec D, et al Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 2005; 106:3457-64.
41. Bossard C, Malard F, Arbez J., Chevallier P, Guillaume T, Delaunay J., et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012; 26:1471-4.
42. Malard F, Bossard C, Brissot E., Chevallier P, Guillaume T, Delaunay J., et al. Increased plasmacytoid dendritic cells and RORgammat-expres-sing immune effectors in cutaneous acute graft-versus-host disease. J Leukoc Biol 2013; 94:1337-43.
43. Yokogawa M, Takaishi M, Nakajima K., Kamijima R, Digiovanni J, Sano S. Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells. Mol Carcinog 2013; 52:760-9.
44. Xu L, Wang C, Zhou Y., Ren T, Wen Z. CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol Lett 2012; 142:55-63.
45. Gautreau L, Chabannes D, Heslan M., Josien R. Modulation of regulatory T cell-Th17 balance by plasmacytoid dendritic cells. J Leukoc Biol 2011; 90:521-7.
46. Yu CF, Peng WM, Oldenburg J, Hoch J., Bieber T, Limmer A, et al Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010; 184:1159-67.
47. Bonnefoy F, Couturier M, Clauzon A., Remy-Martin JP, Gaugler B, Tiberghien P., et al. TGF-beta-exposed plasmacytoid dendritic cells participate in Th17 commitment. J Immunol 2011; 186:6157-64.
48. Numasaki M, Fukushi J, Ono M., Narula SK, Zavodny PJ, Kudo T, et al Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7.
49. Wang L, Yi T, Kortylewski M., Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206:1457-64.
50. Martin-Orozco N., Muranski P, Chung Y., Yang XO, Yamazaki T, Lu S, et al T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31:787-98.
51. Kryczek I, Wei S, Szeliga W., Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114:357-9.
52. Nunez S, Saez JJ, Fernandez D, Flores-Santibanez F, Alvarez K., Tejon G, et al. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology 2013; 139:61-71.
53. Lanca T, Silva-Santos B. Recruitment of gammadelta T lymphocytes to tumors: A new role for the pleiotropic chemokine CCL2. Oncoimmu-nology 2013; 2:e25461.
54. Ben-Baruch A. The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFalpha and Chemokines. Cancer Microenviron 2012; 5:151-64.
55. Ma Y, Mattarollo SR, Adjemian S, Yang H., Aymeric L, Hannani D, et al CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014; 74:436-45.
56. Brackett CM, Muhitch JB, Evans S.S., Gollnick SO. IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol 2013; 191:4348-57.